0001104659-22-127154.txt : 20221215 0001104659-22-127154.hdr.sgml : 20221215 20221215070022 ACCESSION NUMBER: 0001104659-22-127154 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221212 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221215 DATE AS OF CHANGE: 20221215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axcella Health Inc. CENTRAL INDEX KEY: 0001633070 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38901 FILM NUMBER: 221463628 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: THIRD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-868-0949 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: THIRD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Pronutria Biosciences, Inc. DATE OF NAME CHANGE: 20150206 8-K 1 tm2232767d1_8k.htm FORM 8-K
0001633070 false 0001633070 2022-12-12 2022-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 12, 2022

 

 

AXCELLA HEALTH INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-38901   26-3321056
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

840 Memorial Drive
Cambridge, Massachusetts		 02139
(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code: (857) 320-2200

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.001 Par Value   AXLA   Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

  

 

 

 

Item 2.05 Costs Associated with Exit or Disposal Activities.

 

On December 12, 2022, the Board of Directors (the “Board”) of Axcella Health Inc. (the “Company” or “Axcella”), doing business as “Axcella Therapeutics,” approved a reprioritization of its programs for Long Covid Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations to support its streamlined set of priorities. As part of this restructuring, the Board approved a reduction in force of approximately 85% of the Company’s workforce. Robert Crane, the Company’s Chief Financial Officer and Virginia Dean, the Company’s Senior Vice President, Chief People Officer were each part of the reduction in force. The reduction in force is a measure to manage costs and conserve cash resources with the goal of maximizing the opportunities available to Axcella during the Board’s review of strategic alternatives to maximize shareholder value.

 

The Company expects to record a charge of up to $2.1 million in the fourth quarter of 2022 relating to the reduction in force, which is expected to consist of employee severance and other restructuring related costs and expenses. The Company’s management will continue to re-evaluate the estimated costs and expenses set forth above and may revise the estimated restructuring charge as appropriate, consistent with generally accepted accounting principles.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As part of the reduction in force, Robert Crane, the Company’s Chief Financial Officer and principal financial officer and Virginia Dean, the Company’s Senior Vice President, Chief People Officer will step down from their positions effective December 14, 2022.

 

Item 7.01 Regulation FD Disclosure.

 

On December 14, 2022, the Company issued a press release entitled “Axcella Announces Program Reprioritization and Corporate Restructuring.” The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 8.01 Other Events.

 

On December 12, 2022, the Board approved the immediate suspension its EMMPACT Phase 2b clinical trial of AXA1125 for the treatment of NASH, to allow Axcella to focus on AXA1125 for the treatment of Long Covid.

 

 

 

 

On December 14, 2022, the Company announced that it had reached an agreement with SLR Investment Corp. (f/k/a Solar Capital Ltd.) (“SLR”) to paydown its remaining debt obligations under its Loan and Security Agreement.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit 
Number		   Description
99.1   Press Release issued by Axcella Health Inc., doing business as “Axcella Therapeutics,” dated December 14, 2022
104   Cover Page Interactive Data (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AXCELLA HEALTH INC.
   
Date: December 15, 2022 By: /s/ William R. Hinshaw, Jr.
    William R. Hinshaw, Jr.
    Chief Executive Officer, President and Director

 

 

 

 EX-99.1 2 tm2232767d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

 

 

Axcella Announces Program Reprioritization and Corporate Restructuring Move Positions Company to Best Focus on Long COVID Program

 

CAMBRIDGE, Mass., December 14, 2022 – Axcella Therapeutics (Nasdaq: AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. The company has initiated a process to explore a range of strategic alternatives to maximize shareholder value and is working with an investment bank to act as a strategic advisor for this process. As part of this repositioning, and to align with its current capital constraints, the company is announcing a series of organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations to support its streamlined set of priorities.

 

“The strategic process we initiate today prioritizes efforts to support our Long COVID program and will best position us to derive value from our platform technology and its corresponding programs,” said Bill Hinshaw, CEO of Axcella. “We are in active and accelerating business development discussions and are exploring creative collaborations to bring these innovations forward.”

 

Organizational and Program Updates:

 

·Axcella will reprioritize its efforts to focus on the significant unmet need and opportunity presented by Long COVID. Axcella’s Phase 2a clinical trial results demonstrate the potential of AXA1125 to play an important role in treating patients suffering from Long COVID. Axcella’s Phase 2a trial has been the only controlled trial to demonstrate statistically and clinically relevant improvement in fatigue in patients with Long COVID. Axcella is engaged in ongoing and productive reviews with regulators in the U.S. and Europe, and the company is aiming to advance its Long COVID Fatigue program into a potential registration trial.
·Axcella will be discontinuing its ongoing Phase 2b clinical trial of AXA1125 in NASH, while keeping the option to revisit this program should resource availability change. In September, Axcella reported positive data from a preplanned interim analysis from their trial of AXA1125 in NASH. At 24 weeks, there were statistically significant and clinically relevant improvements in the liver stiffness measurement (LSM) compared to placebo in the high dose arm for all subjects and statistically significant improvements in other non-invasive tests of liver fat and stiffness. Axcella’s pre-clinical and clinical trial data for NASH demonstrated relevant activity and established a notable safety record for AXA1125, which the company applied to its clinical trial for Long COVID Fatigue.
·Axcella is realigning the organization to correspond to this shift in strategy and reprioritization of its programs, reducing its workforce by 85 percent, retaining certain employees to execute the strategic process. Among the departing employees are Bob Crane, Chief Financial Officer, and Virginia Dean, Chief People Officer.
·Axcella reached an agreement with SLR Investment Corp. (f/k/a Solar Capital Ltd.) (“SLR”) to paydown the debt obligations of the previous agreement.

 

 1 

 

 

·With respect to the Company’s plans, no assurances can be made as to whether a strategic transaction will be recommended by the Board of Directors, and the Company does not intend to discuss developments with respect to the evaluation process unless a transaction is approved, or disclosure otherwise becomes appropriate.

 

“We are incredibly proud of the work of the entire Axcella team and would like to thank our talented employees for their dedication and contributions to bringing these programs for Long COVID and NASH along on their journeys to the clinic, and to achieving recent major milestones including our promising top line trial data,” continued Hinshaw. “Repositioning the company will best enable us to accelerate the development of AXA1125. We are in active conversations with regulators in both the U.S. and Europe and are enthusiastic about the clinical pathway for AXA1125 and Long COVID Fatigue, a disease that currently has no treatment options.”

 

“We continue to demonstrate the power and scalability of Axcella’s underlying science, and the speed and predictability of the platform our team has built, in a consistent way,” said Margaret Koziel, M.D., Chief Medical Officer of Axcella. “We believe AXA1125 could be an important first line agent for the large and unserved patient populations with Long COVID Fatigue and NASH, and with our current capital constraints, we are realigning our efforts to best preserve the value of our programs and platform.”

 

About Axcella Therapeutics (Nasdaq: AXLA)

 

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella’s pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID, NASH, and the reduction in risk of OHE recurrence. The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

 

Internet Posting of Information

 

Axcella uses the “Investors and News” section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. The information that we post on our website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

 

 2 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the potential utility of AXA1125 as a treatment of Long Covid or NASH, the strength of the Company’s platform and comparison to traditional drug discovery methods, and the ability of the Company to realize the benefits from its strategic reprioritization and organizational restructuring. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the potential impact of COVID-19 on the company’s ability to conduct and complete its ongoing or planned clinical studies and clinical trials in a timely manner or at all due to patient or principal investigator recruitment or availability challenges, clinical trial site shutdowns or other interruptions and potential limitations on the quality, completeness and interpretability of data the company is able to collect in its clinical trials of AXA1125, other potential impacts of COVID-19 on the company’s business and financial results, including with respect to its ability to raise additional capital and operational disruptions or delays, changes in law, regulations, or interpretations and enforcement of regulatory guidance, whether data readouts support the company’s clinical trial plans and timing, clinical trial design and target indications for AXA1125, the clinical development and safety profile of AXA1125 and its therapeutic potential, whether and when, if at all, the company’s product candidates will receive approval from the FDA or other comparable regulatory authorities, potential competition from other biopharma companies in the company’s target indications, and other risks identified in the company’s SEC filings, including Axcella’s Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC. The company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Axcella disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The company explicitly disclaims any obligation to update any forward-looking statements.

 

Company Contact

info@axcellatx.com

 

 3 

 

 EX-101.SCH 3 axla-20221212.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 axla-20221212_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 axla-20221212_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2232767d1_ex99-1img01.jpg GRAPHIC begin 644 tm2232767d1_ex99-1img01.jpg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htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Dec. 12, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 12, 2022
Entity File Number 001-38901
Entity Registrant Name AXCELLA HEALTH INC.
Entity Central Index Key 0001633070
Entity Tax Identification Number 26-3321056
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 840 Memorial Drive
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 857
Local Phone Number 320-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol AXLA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 tm2232767d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001633070 2022-12-12 2022-12-12 iso4217:USD shares iso4217:USD shares 0001633070 false 8-K 2022-12-12 AXCELLA HEALTH INC. DE 001-38901 26-3321056 840 Memorial Drive Cambridge MA 02139 857 320-2200 false false false false Common Stock, $0.001 Par Value AXLA NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://axcellahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2232767d1_8k.htm axla-20221212.xsd axla-20221212_lab.xml axla-20221212_pre.xml tm2232767d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2232767d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2232767d1_8k.htm" ] }, "labelLink": { "local": [ "axla-20221212_lab.xml" ] }, "presentationLink": { "local": [ "axla-20221212_pre.xml" ] }, "schema": { "local": [ "axla-20221212.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "axla", "nsuri": "http://axcellahealth.com/20221212", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2232767d1_8k.htm", "contextRef": "From2022-12-12to2022-12-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://axcellahealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2232767d1_8k.htm", "contextRef": "From2022-12-12to2022-12-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-127154-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-127154-xbrl.zip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

L,2IL"F$XO.VM*)SBR+#AFU_&%.=T;8057@3T9H':,&_"3XWY%O^A8[/LK+ MG_!VQ'Q*$%"6?0_,^[>9NF/[S/:S5U,7V*#+3V\S/IOX>:F<>>R7#\$>_5\V M2TY-9AD'I,?\0]*F(W9 )L;DD+0:XI>;@EJ[^=3[0VV\J]4Z\ /G0[+9I_8N M[M_@?&^6YGD3S?,9P$HGLUX_T[US )^-NT@8S3.M#'HU;+-MCDC$UO M"F"?]HK%PG[A.7"K,;BU$;,-^-\_M>C@ID\MSIX!:N\$B-VX46Y"LR%APJ/G MP%!O>D/J,7ZCW@@K*8%P\>PY$55Q":25PS3&FA/M3B[W-]$$¢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